However, allowing derogations from the rules on data protection and caducity in connection with the market authorisation procedure could give an unfair competitive advantage to manufacturers of generic pharmaceuticals on the European market.
However, allowing derogations from the rules on data protection and caducity in connection with the market authorisation procedure could give an unfair competitive advantage to manufacturers of generic pharmaceuticals on the European market.